Skip to content
Screener

PTC Therapeutics PTCT Business Segments — Segment Reporting Other Item Amount

Similar metrics at other companies

CryoPort, Inc. logo
CYRXLife Sciences Products — Segment Reporting Other Item Amount
$1.29M-13.1%
CryoPort, Inc. logo
CYRXLife Sciences Services — Segment Reporting Other Item Amount
$2.53M-14.2%
Disc Medicine logo
IRONOther Segment Items — Segment Reporting Other Item Amount
$6.02M+2.7%
Eagle Materials logo
EXPCement — Segment Reporting Other Item Amount
$39.3M+56.0%
Escalade logo
ESCASporting Goods — Segment Reporting Other Item Amount
$2.38M-76.7%
Corvex logo
MOVESegment Reporting — Segment Reporting Other Item Amount
$1.42M

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.78B+41.9%
Enterprise value$5.34B+54.9%
P/E7.1×
P/S+4.7×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001070081-26-000012
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Manufacturing costs9,08514,950
Administrative costs16,68818,414
Occupancy costs8,3547,183
Other segment items (a)107,889145,423
Segment net (loss) income$(2,809)$866,562
Reconciliation of profit or loss
Adjustments and reconciling items
Consolidated net (loss) income$(2,809)$866,562

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's business segments — segment reporting other item amount?
PTC Therapeutics (PTCT) reported business segments — segment reporting other item amount of $107.89M in Q1 2026.
How has PTC Therapeutics's business segments — segment reporting other item amount changed year-over-year?
PTC Therapeutics's business segments — segment reporting other item amount decreased by 25.8% year-over-year, from $145.42M to $107.89M.
What is the long-term trend for PTC Therapeutics's business segments — segment reporting other item amount?
Over 3 years (2022 to 2025), PTC Therapeutics's business segments — segment reporting other item amount has grown at a -6.0% compound annual growth rate (CAGR), from $437.41M to $363.61M.
What does business segments — segment reporting other item amount mean?
This captures miscellaneous or non-recurring financial items specific to the life science segment that do not fit into standard operating expense categories. It is used to reconcile segment performance by accounting for unique adjustments, impairments, or one-time charges.

Ask your AI about PTC Therapeutics's business segments — segment reporting other item amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude